2019 ACR/ARP Annual Meeting

November 8-13, 2019. Atlanta, GA.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1501

Ixekizumab: 52-Week Efficacy and Safety in Radiographic Axial Spondyloarthritis Patients with Prior Inadequate Response/Intolerance to Tumor Necrosis Factor Inhibitors
Abstract Number: 1280

JAK Inhibitors: A Promising Molecular-targeted Therapy in Dermatomyositis
Abstract Number: 2468

JAK-STAT Signaling System in Pannus Formation of Psoriatic Arthritis: A Therapeutic Target
Abstract Number: 209

Joint Overuse in Patients with Rheumatoid Arthritis
Abstract Number: 1859

Joint Tenderness and Ultrasound Inflammation in DMARD-naïve Early Rheumatoid Arthritis Patients
Abstract Number: 1338

Joint-specific Responses to Tofacitinib and Methotrexate in Rheumatoid Arthritis: A Post Hoc Analysis of Data from ORAL Start
Abstract Number: PP09

Journeying Towards Hope: Making a Difference in The Lives of Lupus Patients in Mauritius
Abstract Number: 2713

Juvenile Spondyloarthritis in the Childhood Arthritis and Rheumatology Research Alliance (CARRA) Registry: High Biologic Use, Low Prevalence of HLA-B27, and Equal Sex Representation in Those with Sacroiliitis
Abstract Number: 1709

Juvenile-Onset IgG4-Related Disease: A Systematic Review
Abstract Number: 1739

Kawasaki Disease Shock Syndrome – More Common Than We Think: Our Experience at Chandigarh, North India
Abstract Number: 1743

Kawasaki Disease: Is Intravenous Immunoglobulin Alone Adequate for the Child with Kawasaki Disease and Coronary Artery Lesions? A Retrospective Study of 65 Children with Kawasaki Disease from a Single North Indian Centre
Abstract Number: 46

Key Inflammatory Biomarkers at Baseline Are Associated with Filgotinib Response at Week 12 in Rheumatoid Arthritis Patients with Inadequate Response or Intolerance to Biologic DMARDs
Abstract Number: 87

KINE-101, a Novel Synthetic Peptide with Potent Regulatory T Cells Activation to Treat Rheumatoid Arthritis
Abstract Number: 2348

KL-6 Is a Useful Marker to Monitor the Progression of RA-ILD, but Not to Diagnose or Predict the Development of ILD
Abstract Number: 2926

Knee Injury and Transitions Among States of Knee Osteoarthritis in the Johnston County Osteoarthritis Project: A Multi-State Time-To-Event Modeling Approach

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].